Document is current
Any future updates will be listed below
-
Authors
Lee, Holly
Ahn, Sungwoo
Maity, Ranjan
Leblay, Noemie https://orcid.org/0000-0002-4202-7127
Ziccheddu, Bachisio
Truger, Marietta
Chojnacka, Monika https://orcid.org/0000-0001-7176-6108
Cirrincione, Anthony
Durante, Michael https://orcid.org/0000-0003-3137-6847
Tilmont, Remi
Barakat, Elie
Poorebrahim, Mansour
Sinha, Sarthak https://orcid.org/0000-0002-0770-3150
McIntyre, John
M.Y. Chan, Angela
Wilson, Holly
Kyman, Shari https://orcid.org/0000-0001-5386-5866
Krishnan, Amrita
Landgren, Ola https://orcid.org/0000-0001-6485-4839
Walter, Wencke https://orcid.org/0000-0002-5083-9838
Meggendorfer, Manja https://orcid.org/0000-0002-9038-3265
Haferlach, Claudia
Haferlach, Torsten https://orcid.org/0000-0003-0196-2837
Einsele, Hermann https://orcid.org/0000-0002-7680-0819
Kortüm, Martin K. https://orcid.org/0000-0002-7011-0286
Knop, Stefan
Alberge, Jean Baptiste
Rosenwald, Andreas
Keats, Jonathan J. https://orcid.org/0000-0003-4375-7399
Rasche, Leo https://orcid.org/0000-0002-9536-9649
Maura, Francesco https://orcid.org/0000-0002-5017-1620
Neri, Paola
Bahlis, Nizar J. https://orcid.org/0000-0001-7353-7034
- License Information
-
More Information
Article History
Received: 5 March 2023
Accepted: 5 July 2023
First Online: 31 August 2023
Competing interests
: N.J.B. has received research funding from Pfizer and speaker’s bureau honoraria from Amgen, BMS, Sanofi, Pfizer and Janssen; he is a consultant/advisory board member for BMS, Janssen and Pfizer. P.N. received speaker’s bureau honoraria from BMS, Janssen and Sanofi, and is a consultant/advisory board member for BMS and Janssen. C.H. and T.H. have equity ownership of MLL Munich Leukemia Laboratory. O.L. has received research funding from: the National Institutes of Health (NIH), NCI, US Food and Drug Administration, MMRF, International Myeloma Foundation, Leukemia and Lymphoma Society, the Paula and Rodger Riney Myeloma Foundation, Perelman Family Foundation, Rising Tide Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics and Karyopharm; received honoraria and is on advisory boards for Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno and Pfizer; and serves on independent data monitoring committees for clinical trials led by Takeda, Merck, Janssen and Theradex. J.J.K has received research funding from Amgen, Genentech and Janssen, and has received honoraria and is on advisory boards for Janssen. The other authors declare no competing interests.
